12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

J&J sales and marketing update

Johnson & Johnson said it is pursuing multiple options to restore a reliable supply of cancer drug Doxil liposomal doxorubicin. The pharma said its short-term solution includes manufacturing Doxil in collaboration between third-party manufacturer, Ben Venue Laboratories Inc., and another supplier to complete end-to-end...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >